Let's see what this stock has announced on Thursday. The post ASX 200 healthcare stock sinks 9% on FDA update appeared first ...

None of the findings in a new working academic paper will likely surprise financial advisors. But they could provide some ...

Researchers at Baylor College of Medicine report in Science Advances a breakthrough in human norovirus (HuNoV) research.

Pfizer Inc. (NYSE:PFE) is one of the best large cap stocks to buy under $50. On February 3, Pfizer announced positive topline ...

Based on the average office worker salary of those polled being $115,779, this equates to $3 billion lost each working day, ...

1) the active drug substance Axitinib, which used to belong to Pfizer, is an FDA-approved, oral, potent VEGFR inhibitor. So ...

Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company.

The pharmaceutical giant (PFE) said two doses from a Phase 2b study of the once-a-month injection demonstrated weight reduction of 10% and 12.3% after 28 weeks in adults with obesity or overweight ...

Pfizer shares fell 3.3% Tuesday on what some market watchers called underwhelming study results for an experimental weight-loss drug the drugmaker obtained after a contentious and costly bidding war ...

The study, published in The Canadian Medical Association Journal, found there was a 60 percent rise in diagnoses of psychotic ...

A report by the Nasdaq Entrepreneurial Center praises Virginia’s capital for developing high-performing entrepreneurs, but says it needs statewide heft.

Pfizer (PFE) said a Phase 2 study of a drug requiring one injection a month - rather than the once-a-week schedule for existing popular drugs from Eli Lilly and Novo Nordisk - demonstrated ...